Abbott Launches Its TactiFlex Ablation Catheter for Abnormal Heart Rhythm Treatment

Abbott announces the launch of its TactiFlex™, Sensor Enabled™ ablation catheter, the world's first ablation catheter with a flexible tip and contact force technology. Used for ablation procedures to treat atrial fibrillation (AF), the most common abnormal heart rhythm, the TactiFlex™ catheter can reduce procedure time 1 and improve safety compared to the company's previous generation catheters 2 .

More than 37 million people worldwide live with atrial fibrillation 3 and the numbers are expected to more than double by 2050 4 . Another five million 5 cases are diagnosed each year, indicating a growing healthcare challenge that demands innovative solutions for patients and their doctors. In Brazil, estimates indicate that up to 5 million people have the disease – without even knowing it. In practice, one in three people hospitalized with cardiac arrhythmia has atrial fibrillation. Among the elderly, the situation is even more critical. On average, 10% of people over 70 years of age have this health problem 6 .

For those who suffer from atrial fibrillation, daily life can be challenging as people often experience dizziness, chest pain, and heart palpitations. Furthermore, it can lead to a stroke if left untreated, which makes it even more critical that it be treated as soon as possible.

"We are entering a new era of ablation procedures for atrial fibrillation due to new technologies developed, such as Abbott's flexible tip contact force catheter, the TactiFlex. This new catheter along with cutting-edge equipment for mapping arrhythmias cardiac devices, EnSite

New catheters and other cutting-edge solutions from Abbott for patients with atrial fibrillation

The TactiFlex ™ catheter is designed for use with Abbott's EnSite™

Unlike other catheters available on the market, TactiFlex™ uses an innovative design with a laser-cut pattern that flexes when in contact with the heart wall. This helps direct fluid to the treated tissue 1 and allows for more precise catheter positioning – providing twice the stability in a beating heart – for consistent therapy delivery 7 .

"Abbott, being the company with the most complete portfolio for the treatment of cardiac arrhythmias, has been leading this market with the new technologies developed. The EnSite X Electrophysiology System together with the TactiFlex catheter, allow doctors and patients to feel even more confident that ablation procedures will provide increasingly safe and effective results," concludes Letícia.

The recently published TactiFlex AF IDE 8 study presented strong clinical results demonstrating that the catheter created rapid and safe lesions to treat atrial fibrillation with over 99% acute procedural success 1 .

In addition to Brazil, the TactiFlex™ catheter is also approved for use in the United States, Europe, Japan, Africa and Australia. 

Sobre a Abbott

Abbott is a leading global healthcare company that helps people live fully at every stage of life. Our portfolio of technologies that transform people's lives spans the entire healthcare universe, through leading products and businesses in diagnostics, medical devices, nutrition and branded medicines. Our 115,000 employees work to help people in more than 160 countries.

Present in Brazil for more than 85 years, its local strategy aims to provide people with better access to innovative medical and health solutions, contributing to the development of healthcare in the country. In Brazil, the company employs approximately 2,800 employees and its main units are in São Paulo (administrative headquarters); Rio de Janeiro and Belo Horizonte

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!